DoMore Diagnostics develops AI-driven digital pathology diagnostics that predict patient outcomes from routine histology images. Our mission is to personalize cancer treatment decisions, reduce over- and undertreatment, and provide objective prognostic tools that improve patient outcomes and support clinicians worldwide.

Our Histotype Px® platform combines machine learning and digital biomarkers derived from histological images. The company was founded on academic research from institutions including Oslo University Hospital, Oxford University and University College London and grew from a Lighthouse research project led by the late Prof. Håvard Danielsen to translate novel AI methods into clinically validated diagnostics.

DoMore Diagnostics has received support from the European Innovation Council (EIC) Accelerator and works with clinical and commercial partners to validate and deploy its AI diagnostics in real-world settings.